CLINICAL USE

Treatment of urinary frequency, urgency and incontinence

DOSE IN NORMAL RENAL FUNCTION

1–2 mg twice daily M/R: 4 mg daily

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : 475.6
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : 96
  • %Excreted unchanged in urine &nbsp &nbsp : <1

  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp : 0.9–1.6

  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp : 2–3 (10 hours in poor metabolisers)/– MR: 6/–

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

    30–50 Dose as in normal renal function. Use with caution 10–30 1 mg twice daily. Use with caution
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : 1 mg twice daily. Use with caution

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp: Unlikely to be dialysed. Dose as in GFR <10 mL/min

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : Unlikely to be dialysed. Dose as in GFR <10 mL/min
  • HDF/high flux &nbsp : Unlikely to be dialysed. Dose as in GFR <10 mL/min
  • CAV/VVHD &nbsp &nbsp &nbsp: Unlikely to be dialysed. Dose as in GFR=10–30 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • None known

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    OTHER INFORMATION

    Active metabolites may accumulate in renal failure Modified release preparation is not suitable for renal patients Use with caution in patients at risk of QT
    Tags:

    • Related News

    sorafenib.txt

    tamsulosin.txt